Cited by

• Patient-reported outcome measures (PROMs) used among liver transplant recipients: a systematic review and methodological quality appraisal.

  Zhang Q, Chen X, Kang Y, Yu J, Zhang Y. Zhang Q, et al. Qual Life Res. 2025 May;34(5):1179-1193. doi: 10.1007/s11136-025-03893-3. Epub 2025 Jan 20. Qual Life Res. 2025. PMID: 39831937
• Development of a liver graft assessment expert machine-learning system: when the artificial intelligence helps liver transplant surgeons.

  Pontes Balanza B, Castillo Tuñón JM, Mateos García D, Padillo Ruiz J, Riquelme Santos JC, Álamo Martinez JM, Bernal Bellido C, Suarez Artacho G, Cepeda Franco C, Gómez Bravo MA, Marín Gómez LM. Pontes Balanza B, et al. Front Surg. 2023 Sep 22;10:1048451. doi: 10.3389/fsurg.2023.1048451. eCollection 2023. Front Surg. 2023. PMID: 37808255 Free PMC article.
• Current strategies for immunosuppression following liver transplantation.

  Gotthardt DN, Bruns H, Weiss KH, Schemmer P. Gotthardt DN, et al. Langenbecks Arch Surg. 2014 Dec;399(8):981-8. doi: 10.1007/s00423-014-1191-9. Epub 2014 Apr 20. Langenbecks Arch Surg. 2014. PMID: 24748543 Review.
• Macrophage Membrane-Coated Nanoparticles Alleviate Hepatic Ischemia-Reperfusion Injury Caused by Orthotopic Liver Transplantation by Neutralizing Endotoxin.

  Ou Z, Zhong H, Zhang L, Deng M, Zhang W, Wang J, Feng H, Gong J, Miao C, Yi Z. Ou Z, et al. Int J Nanomedicine. 2020 Jun 11;15:4125-4138. doi: 10.2147/IJN.S253125. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32606668 Free PMC article.
• Donor Hepatic Steatosis Induce Exacerbated Ischemia-Reperfusion Injury Through Activation of Innate Immune Response Molecular Pathways.

  Gehrau RC, Mas VR, Dumur CI, Suh JL, Sharma AK, Cathro HP, Maluf DG. Gehrau RC, et al. Transplantation. 2015 Dec;99(12):2523-33. doi: 10.1097/TP.0000000000000857. Transplantation. 2015. PMID: 26285018 Free PMC article.